Abstract Details

Title myMS; A Comprehensive Patient-Centered Mobile App to Monitor MS at Home

Topic Multiple Sclerosis

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-003

Objective

The overall aim of this project is to develop and validate novel digital technologies to capture disease characteristics and to empower patients with multiple sclerosis (MS). A pilot study was conducted using myMS, a comprehensive smartphone application, to compare its active tasks against clinical metrics traditionally used in MS.

Background

Digital health products offer a new data collection strategy and personalized disease management tools. They are gradually winning out on accessibility, efficiency, accuracy and cost effectiveness compared to traditional data collection methods for complex diseases like MS where patients experience daily fluctuating symptoms. Since this technology is scalable, it can allow the collection of a high-quality BigData set worldwide.

Design/Methods myMS uses a comprehensive approach to collect clinical (ambulation, cognition, vision, QOL, Rx, diet, MS and childhood history, exercise habits, comorbidities), genetic (~1,000,000 SNPs, FDA-approved 23andMe reports), and MRI (visualization and quantification) data that could interface with wearable devices (iPhone or Android). The pilot study included 200 U.S. participants who used myMS and a sub-study (n=75) conveniently sampled at USC to compare its active tasks (6Mapp, COGapp, VISapp) against EDSS, T25FW, Symbol-Digit-Modality-Test (SDMT), and low contrast visual acuity (LCVA).

Results After uploading MRI images on a dedicated website, 200 participants completed enrollment from home and met inclusion criteria based on MRI dissemination in time. Participants were able to register and receive 23andMe genetic kits at home and complete surveys and active tasks. Cross-sectional Spearman correlation analysis showed modest to strong correlation (p<0.01) between 6Mapp-25FWT (r=-0.85); 6Mapp-EDSS (r=-0.31); COGapp-SDMT (r=0.69); and VISapp-LCVA (r=0.67).

Conclusions myMS can be used successfully outside of clinical visits with minimal supervision and instructions. Frequent notifications, personalized dashboard, and incentives such as genetic reports and browsing of MRI images increase participation and adherence. 6Mapp, COGapp, VISapp were significantly correlated with EDSS, 25FWT, SDMT, and LCVA, providing preliminary validation of myMS.

Authors/Disclosures
Daniel Pelletier, MD (Keck School of Medicine of USC) PRESENTER	Dr. Pelletier has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Pelletier has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi Genzyme. Dr. Pelletier has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Pelletier has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Polpharma Biologics.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��